USPTO Grants Re-Exam Of Merck Singulair Patent
The U.S. Patent and Trademark Office has granted a request to re-examine a Merck & Co. patent covering blockbuster allergy drug Singulair that is at the center of a patent dispute...To view the full article, register now.
Already a subscriber? Click here to view full article